Clinical Research Directory
Browse clinical research sites, groups, and studies.
Sublingual Buprenorphine Through Telemedicine vs In-Person Care as Usual
Sponsor: New York State Psychiatric Institute
Summary
This study will compare in-person induction and maintenance dosing of sublingual buprenorphine to induction and maintenance dosing of sublingual buprenorphine through comprehensive telehealth sessions and telehealth medication for opioid use disorder (MOUD).
Official title: A Randomized, Controlled Trial of Sublingual Buprenorphine Through Telemedicine vs In-Person Care as Usual in the Treatment of Opioid Use Disorder
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2026-02-01
Completion Date
2026-12-31
Last Updated
2025-10-31
Healthy Volunteers
No
Conditions
Interventions
Buprenorphine SL
Up to 24 mg per day
Telehealth
Telehealth MOUD, utilizing a standardized protocol for each healthcare provider session
In-person treatment as usual
in-person induction and maintenance dosing of sublingual buprenorphine, or MOUD as usual.